Search

Displaying results 9441 - 9450 of 10000 in total
  1. Drug

    Cutamesine

    go.drugbank.com/drugs/DB06618
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Amdoxovir

    go.drugbank.com/drugs/DB06619
    Investigational

    Synonyms: beta-D-2,6-Diaminopurine-dioxolaneCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)

  4. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic IndexSynonyms: 4-AP, 4-Aminopyridine
  7. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  8. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  9. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Clazosentan

    go.drugbank.com/drugs/DB06677
    Investigational

    Categories: Receptor, Endothelin A, Heterocyclic Compounds, 1-Ring